Armadin
Armadin Raises $255.5M Series B for Autonomous Security
Armadin announced $255.5M in Series B financing on October 1, 2026. Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Round details
The financing includes backing from Andreessen Horowitz, Accel, Bain Capital Ventures, Redpoint, 8VC, Ballistic Ventures, Google Ventures, In-Q-Tel. The company reported a $2.5B+ valuation alongside the transaction.
- Round: Series B
- Capital announced: $255.5M
- Total funding reported: $445M
How the company plans to use the capital
Armadin will use the investment to scale its agentic security platform and to expand its research, training, and go-to-market efforts.
Why this matters for GTM teams
The round shows investors continuing to back AI-native cybersecurity, with the company arguing that frontier AI models compress the time between vulnerability disclosure and working exploit, so periodic penetration tests cannot keep pace.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Armadin Series B announcement.
Company Info
Investors (8)
Share
Related Reports
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free